BCL2 and lymphoma: One of the strategies to avoid acquired resistance and to increase the clearance of malignant lymphocytes is the combinations of PI3K inhibitors with other anti-lymphoma agents, including anti-CD20 antibodies, BTK inhibitors, or BCL2 inhibitors [138,139].